Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 February 2014Website:
http://www.revance.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:58:50 GMTDividend
Analysts recommendations
Institutional Ownership
RVNC Latest News
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.74 per share a year ago.
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
What type of business is Revance Therapeutics?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
What sector is Revance Therapeutics in?
Revance Therapeutics is in the Healthcare sector
What industry is Revance Therapeutics in?
Revance Therapeutics is in the Biotechnology industry
What country is Revance Therapeutics from?
Revance Therapeutics is headquartered in United States
When did Revance Therapeutics go public?
Revance Therapeutics initial public offering (IPO) was on 06 February 2014
What is Revance Therapeutics website?
https://www.revance.com
Is Revance Therapeutics in the S&P 500?
No, Revance Therapeutics is not included in the S&P 500 index
Is Revance Therapeutics in the NASDAQ 100?
No, Revance Therapeutics is not included in the NASDAQ 100 index
Is Revance Therapeutics in the Dow Jones?
No, Revance Therapeutics is not included in the Dow Jones index
When was Revance Therapeutics the previous earnings report?
No data
When does Revance Therapeutics earnings report?
The next expected earnings date for Revance Therapeutics is 28 February 2025